Why Altria Stock Sagged on Wednesday

By Eric Volkman – Apr 1, 2026 at 6:47PM ESTKey PointsThis is affecting an FDA fast-track approval program, according to a news agency's report.The resistance to tobacco products just doesn't seem to be melting away.Altria (MO 0.80%) stock couldn't quite make it over the hump of Hump Day. Investors traded out of tobacco titles generally on a media report that certain products in a regulator's fast-track approval program might not be approved quickly after all. While Altria wasn't as affected as other tobacco companies in the ensuing rout, it did suffer a share price decline of almost 1% on the day. The problem with pouches That fast-track program was devised by the U.S. Food and Drug Administration (FDA), which looks like it might be slow-walking the initiative. An article published Wednesday morning by Reuters, citing three unidentified sources, said that scientists at the regulator are hesitant to authorize the sale of nicotine pouch products currently under consideration. Image source: Getty Images. Such goods deliver nicotine to users in a small sack that's placed in the mouth. This represents something of an evolution from traditional "chew," in which a plug of tobacco is absorbed in this manner. On the back of that report, investors understandably traded out of tobacco stocks eagerly. The main reason Altria wasn't hit as badly is that six varieties of its on! PLUS line were the first pouch products approved under that fast-track program. ExpandNYSE: MOAltria GroupToday's Change(-0.80%) $-0.53Current Price$65.46Key Data PointsMarket Cap$110BDay's Range$63.68 - $65.7352wk Range$52.82 - $70.51Volume831KAvg Vol10MGross Margin75.86%Dividend Yield6.36% Regulatory push-back So Altria effectively got in under the wire with those on! PLUS goods. Still, the Reuters report -- if accurate -- indicates that the folks in our government responsible for giving the nod to tobacco products aren't very keen to do so for certain offerings. This doesn't bode particularly well for any company in the business, even if they've benefited from the regulator's green light recently. Read NextMar 31, 2026 •By Stefon WaltersUp More Than 12% This Year, Is This Dividend Stock With an Ultra-High Yield a No-Brainer Buy?Mar 31, 2026 •By Jeremy BowmanThe Major Long-Term Risk Facing Altria Stock in 2026Mar 30, 2026 •By James BrumleyAltria's Oral Nicotine Pouch Product Is Going Nationwide. Is the Stock a Buy in 2026?Mar 27, 2026 •By Jeremy BowmanWhy Altria Stock Closed Up TodayMar 24, 2026 •By Justin PopeBest Stock to Buy and Hold Forever: Altria Group vs.

Philip Morris InternationalMar 17, 2026 •By Jason HallDividend Kings of 2026About the AuthorEric Volkman is a contributing Motley Fool finance and stock market analyst. Previously, Eric was an equities analyst at European investment bank Raiffeisen Capital and Investment. He’s also been a freelance finance writer since 1995. He studied at Susquehanna University.TMFVolkmanStocks MentionedAltria GroupNYSE: MO$65.48(-0.77%)-$0.51*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.